Nanjing-headquartered biotech company Vazyme Biotech Co., Ltd on Friday said it has raised 550 million yuan ($78 million) in a Series C round of financing led by state-owned China Life Insurance Group’s healthcare fund.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
